^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

self-amplifying RNA cancer vaccine

i
Other names: self-amplifying RNA cancer vaccine, RNA cancer vaccine
Associations
Company:
Boehringer Ingelheim, University of California
Drug class:
Immunostimulant
Related drugs:
Associations
over3years
Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
P1/2, N=56, Active, not recruiting, Ludwig Institute for Cancer Research | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Oct 2021
Clinical • Enrollment closed • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • BI 1361849 • self-amplifying RNA cancer vaccine